PharmaMar and Luye Pharma Launch Their Lung Cancer Drug in China · Global Voices

PharmaMar, a global leader in research, development and marketing of marine cancer therapies, has launched in China, together with its partner Luye Pharma Group, the drug Zepzelca (Lurbinectedin) for the treatment of adult patients with small cell lung cancer, with disease progression during or after receiving platinum-based chemotherapy. The launch took place as part of a scientific event organized by the China Cancer Association (C.A.C.A.), on…